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Abstract.
BACKGROUND: The debilitating fatigue that patients with multiple sclerosis (MS) commonly experience during day-to-day
living activities responds poorly to current therapeutic options. Direct currents (DC) delivered through the scalp (transcranial
DC stimulation or tDCS) at weak intensities induce changes in motor cortical excitability that persist for almost an hour after
current offset and depend on current polarity. tDCS successfully modulates cortical excitability in various clinical disorders but
no information is available for MS related fatigue.
OBJECTIVE: In this study we aimed to assess fatigue symptom after five consecutive sessions of anodal tDCS applied over the
motor cortex in patients with MS.
METHODS: We enrolled 25 patients with MS all of whom experienced fatigue. We delivered anodal and sham tDCS in random
order in two separate experimental sessions at least 1 month apart. The stimulating current was delivered for 15 minutes once
a day for 5 consecutive days. In each session the Fatigue Impact Scale (FIS) and the Back Depression Inventory (BDI) were
administered before the treatment (baseline), immediately after treatment on day five (T1), one week (T2) and three weeks (T3)
after the last tDCS session.
RESULTS: All patients tolerated tDCS well without adverse events. The fatigue score significantly decreased after anodal tDCS
in 65% of the patients (responders). After patients received tDCS for 5 days their FIS scores improved by about 30% and the
tDCS-induced benefits persisted at T2 and T3.
CONCLUSION: Our preliminary findings suggest that anodal tDCS applied over the motor cortex, could improve fatigue in
most patients with MS.
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1. Introduction
Patients with multiple sclerosis (MS) commonly
complain of fatigue. About 75% of patients suffer from
severe fatigue at some point in the disease course (Bak-
shi, 2003; Kos et al., 2008). Fatigue severely limits
patients’ social life and induces marked disability. Cur-
rently approved treatments for MS have only a limited
1053-8135/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
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effect on fatigue (Amato & Portaccio, 2012) and other
newer treatment options often achieve scarce bene-
fit, have high costs and may induce toxicity. Another
concern is worsening fatigue related to depression, a
frequent comorbidity in MS (Bakshi et al., 2000).
Fatigue related to MS, especially in patients with pri-
mary or secondary progressive disease, may manifest
at any stage of the illness. Although the pathogene-
sis involves both central and peripheral abnormalities
central changes probably play the major role. Central
fatigue probably arises through three main neurophys-
iological mechanisms: slow conduction along central
motor pathways leading to reduced spinal motoneu-
ron recruitment (Gandevia, 2001; Racinais et al., 2007;
Sheean et al., 1997), a frequency-dependent conduc-
tion block at Ranvier’s nodes (Sheean et al., 1997) and
impairment of cortical areas involved in motor plan-
ning (i.e. the prefrontal cortex) (Leocani et al., 2001;
Roelcke et al., 1997).
Current treatment options for MS-related fatigue
such as amantadine (Krupp et al., 1995; Pucci et al.,
2007), modafinil (Lange et al., 2009; Moller et al., 2011)
and serotonin reuptake inhibitors failed to demonstrate
significant benefit in controlled trials (Stankoff et al.,
2005).
Transcranial direct current stimulation (tDCS) is
a simple, inexpensive, non invasive technique that
can induce sustained excitability changes in relatively
restricted human brain areas (Nitsche & Paulus, 2000;
Priori, 2003). tDCS applied to the motor area for a few
minutes in a group of a healthy subjects significantly
increased the endurance time for an isometric elbow
flexor muscle contraction without inducing adverse
effects. Although the real explanation remains unclear,
tDCS could benefit muscle fatigue through several
mechanisms, for example by facilitating voluntary acti-
vation or modulating the brain inhibitory feed-back
system. Because central fatigue may depend on frontal
area hypoactivation (Roelcke et al., 1997; van Duinen
et al., 2007) tDCS could also benefit patients by restor-
ing activation in prefrontal areas. Finally, central fatigue
in MS may depend at least in part on a functional discon-
nection between frontal areas and thalamus (DeLuca
& Nocentini, 2011) probably induced by a dopamine
deficiency (Ziv et al., 1998). tDCS could improve the
connectivity between these two structures. No studies
have investigated whether tDCS improves fatigue in
patients with MS, information on its benefits or failure
might give patients with MS a new treatment option.
We designed this study to assess whether tDCS over
the motor area in the cerebral cortex influenced the
symptom fatigue in MS. To do so, in a group of 25
patients we stimulated the cortical motor area for five
days with anodal tDCS delivered for 15 minutes at
1.5 mA or sham tDCS and evaluated fatigue symptoms
with Fatigue Impact Scale (FIS) before and for 3 weeks
after treatment ended.
2. Methods
2.1. Patients
We selected 25 patients (18 women and 7 men; age
range 23–70 years) with MS diagnosed according to
McDonald’s criteria (McDonald et al., 2001): 22 had
relapsing-remitting and 3 patients secondary progres-
sive MS (Table 1). To be enrolled patients had to have
experienced chronic fatigue for at least 6 months with
a global score on the Modified Fatigue Impact Scale
(MFIS) > 45 (Kos et al., 2005; Tellez et al., 2005), and
an Expanded Disability Status Scale (EDSS) (Kurtzke,
1983) score ranging from 0 to 6.5. All patients were
screened and recruited at the Multiple Sclerosis Center,
Fondazione IRCCS Ca’ Granda of Milan. Exclusion
criteria were relapse or corticosteroid course in the
2 months before tDCS, pregnancy or breastfeeding;
patients were also excluded if they had a history of
other neurological or psychiatric disorders. Disease-
modifying therapies such as beta interferon, glatiramer
acetate, azathioprine, or methotrexate were allowed, but
patients had to be receiving a stable dose for at least
2 months. All symptomatic treatment for fatigue was
withdrawn at least 14 days before tDCS. Throughout
the tDCS study patients continued taking the same med-
ications at the same doses used during the previous 2
months. The study was conducted according to the Dec-
laration of Helsinki and approved by the institutional
review board. Patients and their caregivers gave their
informed consent before participation.
2.2. Experimental protocols
tDCS was bilaterally delivered with a constant direct
current stimulator (HDCKit, Newronika, Italy) con-
nected to three sponge electrodes (5 × 7 cm), two
placed on the scalp over the motor cortex bilaterally (C3
and C4 scalp position of the international EEG 10/20
system) and one placed over the right deltoid muscle.
The stimulating current was an anodal DC at 1.5 mA
intensity delivered for 15 minutes, once a day for 5 con-
secutive days. tDCS polarity refers to the electrode over
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Table 1
Clinical features in the 23 patients with multiple sclerosis
Subjects Gender Age (years) Duration of illness (years) EDSS scores Type
Responders 11 Female 40.3 ± 2.3∗ 12.6 ± 1.4 3 ± 0.4 13 SM-RR
(n = 15) 2 SM-SP
Non-responders 5 Female 52.5 ± 4.1∗ 14.4 ± 5 3.8 ± 0.7 6 SM-RR
(n = 8) 2 SM-SP
F: female; M: male; EDSS: Expanded Disability Status Scale; SM-SP: secondary progressive; SM-RR: relapsing remitting; ∗significant difference
p < 0.05. All values are expressed as means ± SEM.
Table 2
Results for the Fatigue Impact Scale (FIS) assessed before and at three timepoints during a 3-week follow-up after the 23 patients received
anodal and sham transcranial direct current stimulation (tDCS)
ANODAL SHAM
T0 T1 T2 T3 T0 T1 T2 T3
Responders 59.5 ± 7.1 38.5 ± 4.1 40.9 ± 5.2 39.9 ± 5.2 49.8 ± 7 43.1 ± 5.4 40.9 ± 7 39.3 ± 6.5
Non-responders 58.5 ± 10.7 61 ± 10.7 46.1 ± 12.6 49 ± 12.8 61 ± 11.4 52.5 ± 12.8 46.3 ± 13.6 51.8 ± 13.3
T0: baseline; T1: immediately after treatment on day five; T2: one week after the end of treatment; T3: 3 weeks after the last tDCS session. All
values are expressed as means ± SEM.
the scalp. For placebo DC, electrodes were placed as for
real stimulation but the stimulator was turned off after
10 s. The subjects therefore felt the initial itching sen-
sation when stimulation began but thereafter received
no current.
Anodal and sham (i.e. placebo) tDCS were tested
in random order in two separate experimental sessions
held at least 1 month apart. The patients and the exam-
iner who did the ratings were blind to the type of tDCS
delivered in each session. The person who applied tDCS
was aware of its polarity. In each session, all patients
completed the following assessment scales before the
treatment (baseline), immediately after treatment on
day five (T1), one week (T2) and three weeks (T3) after
the last tDCS session at the same time of day.
2.3. Scales
2.3.1. Fatigue Impact Scale (FIS)
Fatigue was evaluated using the Italian version of the
Fatigue Impact Scale (FIS) (Fisk et al., 1994). The FIS
consists of 40 items including three subscales: cogni-
tive, physical and psychosocial functioning. Each item
was scored on a five-point scale from 0 (no fatigue) to
4 (severe fatigue).
2.3.2. Back Depression Inventory (BDI)
Mood was evaluated with the 21-item Back Depres-
sion Inventory (BDI) (Beck et al., 1961). The BDI
is a 21-question multiple-choice self-report inventory
that consists of items relating to depressive symptoms
such as hopelessness and irritability, cognitive symp-
toms such as guilt or feelings of being punished as well
as physical symptoms such as fatigue, weight loss and
lack of interest in sex.
2.4. Data analysis
We collected the data for demographic character-
istics (age, duration of disease and severity of the
disease as measured by the EDSS). Wilcoxon test was
used to compare baseline performance. The Fried-
man test was used to compare all scale scores (FIS
and BDI) at baseline and after real or sham tDCS
[stimulation: Anodal-Cathodal; time: Baseline-T1] and
to compare the effect over time for each stimulation
[time: baseline-T1-T2-T3]. Dunn’s multiple compar-
ison test was used for post hoc analysis (p < 0.05).
Patients were further sub-grouped: patients with pos-
itive responses after anodal tDCS were defined as
‘responders’ and those whose responses remained
unchanged after anodal tDCS were defined as ‘non-
responders’. We used the Spearman test to evaluate
a possible correlation between tDCS-induced changes
in fatigue with patients’ demographic characteristics.
Unless otherwise indicated all values are expressed a
means ± SEM. P values <0.05 were considered to indi-
cate statistical significance.
3. Results
During the study two patients experienced a skin
reaction and decided to withdraw. Both adverse
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reactions healed spontaneously within a few weeks.
These two patients were considered as drop-outs. None
of the other subjects reported adverse reactions after
real or placebo tDCS.
When we checked comparability by analyzing our
main outcome measure, our patients’ performance on
the FIS, we found no significant baseline differences
between individual patients (p = 0.3). Significant cor-
relations were found between fatigue improvement as
indexed by FIS and age (p = 0.02), but not with dura-
tion of disease (p = 0.9) and severity of MS (p = 0.3).
FIS total scores improved more in younger than in older
patients.
A preliminary data analysis showed that overall
fatigue assessed at T1 improved significantly after
anodal tDCS (T0 vs. T1, p = 0.02) but not after sham
tDCS (T0 vs. T1, p = 0.2). Data for individual responses
showed that whereas the fatigue score measured at T1
improved from baseline in 15 patients (about 2/3) and
the improvement persisted at the further follow-up visits
(responders) at one week and three weeks, in 8 patients
it remained unchanged from baseline also at the subse-
quent follow-up evaluations (non-responders). Further
data were therefore analyzed separately for the two
groups (Table 2).
The two groups were well-matched for duration
and severity of disease (p > 0.05), but they differed in
age (p = 0.016): responders were younger than non-
responders (the average difference between the two
groups was 12.2 years).
3.1. Responders
After patients received anodal tDCS for 5 days their
fatigue scores on the FIS improved by about 30%
(range 2%–70%) and the tDCS-induced benefits per-
sisted about 1 month after treatment ended. At T1,
after patients received anodal tDCS their FIS total score
significantly decreased whereas after sham-placebo
tDCS it remained unchanged (p = 0.009; post hoc:
anodal T0 vs. T1. p < 0.01). The anodal tDCS-induced
benefit persisted at the follow up-visit (p = 0.08; T0
vs. T1 p < 0.001; T0 vs. T2 p < 0.05; T0 vs. T3
p < 0.05) whereas the sham tDCS-induced benefit did
not (p = 0.1) (Fig. 1). Anodal and sham tDCS left BDI
unchanged (p > 0.05).
No correlations were found between fatigue
improvement as indexed by FIS and age (p = 0.08),
duration of disease (p = 0.2) and severity of MS
(p = 0.6).
3.2. Non-responders
Neither anodal or sham tDCS at the follow-up visit
improved ‘non-responders’ fatigue scores (p = 0.07).
Anodal and sham tDCS also left the other variables
assessed unchanged (BDI, p > 0.05). No correlations
were found between fatigue improvement as indexed
by FIS and age (p = 0.7), duration of disease (p = 0.6)
and severity of MS (p = 0.8).
Fig. 1. Effects of transcranial direct current stimulation (tDCS) on Fatigue Impact Scale (FIS) total score in responder patients. (A) The red line
indicates baseline values as 100%, and values are calculated as % of baseline values. T1 (light grey bars) represents the last tDCS session, T2 (dark
grey bars) one week and T3 (black bars) three weeks thereafter. Error bars are SEM. Note that after anodal tDCS the FIS total score improved
significantly whereas after sham tDCS the scores remained unchanged. ∗p < 0.05. (B) Percentage change after anodal (red lines) and sham (black
lines) tDCS for the single responder patients. Dot lines represent the mean. Data are variations in FIS score expressed as % of baseline values (0
indicates baseline).
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4. Discussion
The main finding is that anodal tDCS delivered for
15 minutes at 1.5 mA over the motor area in the cere-
bral cortex improves fatigue symptoms in most patients
with MS. Though about 1/3 of patients of patients failed
to improve (non-responders), about 2/3 improved sig-
nificantly and persistently (responders). Sham tDCS
left fatigue symptoms almost unchanged over time
thus showing that fatigue improvement is a treatment-
specific effect.
Because fatigue improved slightly though non-
significantly also after sham tDCS we cannot exclude
a placebo effect contribution especially after 1 and 3
weeks. We nevertheless consider it unlikely because
immediately after tDCS sham tDCS left FIS scores
unchanged whereas anodal tDCS improved them
significantly.
The first question these findings raise is how anodal
tDCS improves fatigue related to MS. Anodal tDCS
might have benefitted our responder patients with
MS through several mechanisms, including its known
antidepressant effect (Brunoni et al., 2012). We can
confidently exclude this possibility first because our
patients had normal BDI scores for depression and
second because even though tDCS improved fatigue
it left our patients’ depression scales at T2 almost
unchanged. Another possibility is that tDCS mod-
ulates brain neurochemical content thus improving
motor system input-output function. For example, in an
experiment combining tDCS with magnetic resonance
imaging (MRI) spectroscopy Rango et al. demon-
strated that in healthy subjects tDCS significantly and
remarkably increased brain myo-inositol (Rango et al.,
2008). Brain myo-inositol is an important component
in the second messenger system throughout the brain
and its increase could improve the neural pathways
involved in force generation and endurance. Anodal
tDCS might have improved fatigue by decreasing intra-
cortical GABA activity. This reduction could act either
to compensate the impaired central drive (Benwell
et al., 2007) or to allow subjects to acquire a new
motor skill during exercise (Blicher & Nielsen, 2009).
Another possibility is that anodal tDCS increases neu-
ronal and axonal excitability in the human motor cortex
(Nitsche et al., 2002; Priori et al., 1998). Because the
basic pathophysiological abnormality in MS is a defect
in saltatory conduction due to demyelization, a sub-
threshold electrotonic effect secondary to anodal tDCS
could improve axonal conduction along the demyeli-
nated axonal portion. Anodal tDCS might also have
transiently facilitated thalamocortical afferents thus
enhancing their output to the motor cortex (Leocani et
al., 2001). Finally, putative mechanisms linking central
fatigue to demyelinization process include the func-
tional uncoupling of regions implicated in movement
planning (DeLuca et al., 2009; Sheean et al., 1997),
and tDCS could improve fatigue by ameliorating the
interconnections between different cortical motor areas
(Lang et al., 2004; Williams et al., 2010). Yet a rest-
ing state MRI study (Keeser et al., 2011; Pena-Gomez
et al., 2012; Polania et al., 2012) showed that tDCS
modifies resting-state brain connectivity and could
through this mechanism also improve fatigue in MS
(Filippi et al., 2012; Rocca et al., 2012). Although the
neuro-chemical and neuro-immunological mechanisms
underlying fatigue in MS are still largely unknown,
given that the constant electric field influences ongo-
ing inflammatory processes (Rueger et al., 2012) tDCS
could benefit patients also through this mechanism.
An intriguing issue is why some patients responded
whereas other did not. Our study cannot address this
unexpected finding but the only difference we found
between the two groups was the responders’ younger
age. This finding could imply that lesions and the patho-
logical abnormalities are less severe in responders than
in non-responders thus leaving more space for func-
tional improvement. Against this hypothesis, however,
is the observation that no correlation was found between
the duration of disease and improvement in responders.
Hence an alternative possibility is that the young brain is
more susceptible than the older brain to neuroplasticity
and hence to the tDCS-induced changes (Boggio et al.,
2010; Ross et al., 2011). Finally, studies in depression
have shown that genetic polymorphism can influence
the response to tDCS (Antal et al., 2010; Malaguti et al.,
2011) and other antidepressant treatments (Tsuchimine
et al., 2012; Weizman et al., 2012). Along this line of rea-
soning, the same influence from genetic polymorphism
would apply to the tDCS-induced changes in fatigue in
patients with MS. Interestingly, the same response het-
erogeneity has been reported for other treatments used
for MS (Kuspinar et al., 2012). Whatever the underly-
ing mechanism, our results are encouraging because the
tDCS technique is simple, safe, and well-tolerated and
can be used in a large number of patients.
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